[go: up one dir, main page]

UA42061C2 - Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса - Google Patents

Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса

Info

Publication number
UA42061C2
UA42061C2 UA97115326A UA97115326A UA42061C2 UA 42061 C2 UA42061 C2 UA 42061C2 UA 97115326 A UA97115326 A UA 97115326A UA 97115326 A UA97115326 A UA 97115326A UA 42061 C2 UA42061 C2 UA 42061C2
Authority
UA
Ukraine
Prior art keywords
proton pump
pharmaceutical composition
oral pharmaceutical
composition
composition containing
Prior art date
Application number
UA97115326A
Other languages
English (en)
Russian (ru)
Inventor
Кошик Дж. Дейв
Джеймс Б. Уілльямс
Джеймс Б. Уильямс
Original Assignee
Мерк Енд Ко, Інк
Мерк энд Ко, Инк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Енд Ко, Інк, Мерк энд Ко, Инк filed Critical Мерк Енд Ко, Інк
Publication of UA42061C2 publication Critical patent/UA42061C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

У даному винаході пропонується стабільна пероральна фармацевтична композиція у формі пасти, що містить у якості активного інгредієнту інгібiтор протонного насосу. Композиція придатна для доставки лабільних у кислоті лікарських засобів тваринам, зокрема коням, та людям, що мають складнощі під час ковтання твердих лікарських форм, таких як таблетки та капсули. Більш конкретно, дана композиція містить: один або декілька інгібіторів протонного насосу, гідрофобний олійний носій, підлуговуючий агент та загусник.
UA97115326A 1995-04-04 1996-03-29 Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса UA42061C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/416,275 US5708017A (en) 1995-04-04 1995-04-04 Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
PCT/US1996/004355 WO1996031213A1 (en) 1995-04-04 1996-03-29 Pharmaceutical composition containing proton pump inhibitors

Publications (1)

Publication Number Publication Date
UA42061C2 true UA42061C2 (uk) 2001-10-15

Family

ID=23649308

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97115326A UA42061C2 (uk) 1995-04-04 1996-03-29 Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса

Country Status (29)

Country Link
US (1) US5708017A (uk)
EP (1) EP0819004B1 (uk)
JP (1) JP4603631B2 (uk)
KR (1) KR100419105B1 (uk)
CN (1) CN1080119C (uk)
AT (1) ATE438380T1 (uk)
AU (1) AU703755B2 (uk)
BR (1) BR9604803A (uk)
CA (1) CA2217515C (uk)
CY (1) CY2613B2 (uk)
CZ (1) CZ287297B6 (uk)
DE (1) DE69637985D1 (uk)
DK (1) DK0819004T3 (uk)
EA (1) EA000087B1 (uk)
EE (1) EE03473B1 (uk)
ES (1) ES2329098T3 (uk)
HU (1) HU227864B1 (uk)
IS (1) IS2706B (uk)
MX (1) MX9707694A (uk)
NO (1) NO312994B1 (uk)
NZ (1) NZ305708A (uk)
PL (1) PL183144B1 (uk)
PT (1) PT819004E (uk)
SI (1) SI0819004T1 (uk)
SK (1) SK282872B6 (uk)
TR (1) TR199701117T1 (uk)
UA (1) UA42061C2 (uk)
WO (1) WO1996031213A1 (uk)
ZA (1) ZA962657B (uk)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK173431B1 (da) 1998-03-20 2000-10-23 Gea Farmaceutisk Fabrik As Farmaceutisk formulering omfattende en 2-[[(2-pyridinyl)methyl]sulfinyl]benzimidazol med anti-ulcusaktivitet samt fremgangs
WO1999053918A1 (en) * 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
EP1105387B1 (en) * 1998-08-10 2003-01-29 Winston Pharmateuticals LLC Prodrugs of proton pump inhibitors
EP1119366B1 (en) * 1998-10-06 2003-03-26 Mars Uk Limited Animal stereotypy
AU771061B2 (en) * 1999-02-23 2004-03-11 Merck Sharp & Dohme Corp. Pharmaceutical composition containing proton pump inhibitors
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
ES2288876T3 (es) 1999-10-20 2008-02-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento para estabilizar compuestos de bencimidazol.
GB2358136A (en) * 2000-01-15 2001-07-18 Univ Montfort A medicament for the treatment of equine oral stereotypies using a pH regulator
US6787342B2 (en) * 2000-02-16 2004-09-07 Merial Limited Paste formulations
BR0111215A (pt) * 2000-05-30 2003-12-16 Merial Ltd Métodos para prevenção de úlceras e aperfeiçoamento de desempenho fisiológico
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
WO2002032427A1 (en) * 2000-10-20 2002-04-25 Galephar M/F Stable oral formulation containing benzimidazole derivative
JP4451061B2 (ja) * 2000-10-27 2010-04-14 レオ ファーマ アクティーゼルスカブ 少なくとも１つのビタミンｄまたは１つのビタミンｄアナログおよび少なくとも１つのコルチコステロイドを含有する局所用組成物
JP5009482B2 (ja) * 2000-12-07 2012-08-22 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸に不安定な活性成分を含有する懸濁液の形の製薬製剤
US7988999B2 (en) * 2000-12-07 2011-08-02 Nycomed Gmbh Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
WO2003034837A1 (en) * 2001-10-26 2003-05-01 John Kohnke Products Pty Ltd Dosage system & dosage vehicle therefor
AUPS244002A0 (en) * 2002-05-20 2002-06-13 John Kohnke Products Pty Ltd Agent delivery system
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
CA2490142A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
PT1556371E (pt) * 2002-07-19 2006-09-29 Winston Pharmateuticals Llc Derivados de benzimidazole e sua utilizacao como pro-farmacos de inibadores da bomba de protoes.
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
US9060959B2 (en) * 2003-01-24 2015-06-23 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Synergistic compositions and method for potentiating anti-oxidative activity
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
JP2007523164A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターに関連する化合物の静脈内投与のための方法および組成物
WO2005082337A2 (en) * 2004-02-18 2005-09-09 Allergan, Inc. Compositions comprising prodrugs of proton pump inhibitors
US20080287502A1 (en) * 2004-03-30 2008-11-20 Dermatrends, Inc. Transdermal Administration of Proton Pump Inhibitors
AU2005249367A1 (en) * 2004-04-16 2005-12-15 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8394409B2 (en) * 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
HUE029222T2 (en) * 2006-01-27 2017-02-28 Univ Yale Fast acting gastric acid secretion inhibitor
WO2007112581A1 (en) * 2006-04-03 2007-10-11 Isa Odidi Controlled release delivery device comprising an organosol coat
US10960077B2 (en) * 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
WO2008036201A1 (en) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
AU2007317561A1 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
EP2142432A1 (en) 2007-03-30 2010-01-13 Enterprises International, Inc. Strapping track assembly and method of using the same
AU2009215514B9 (en) 2008-02-20 2014-01-30 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
CN103550214A (zh) * 2008-03-26 2014-02-05 塔罗制药北美有限公司 用于口服药剂的稳定脂质组合物
HRP20170929T1 (hr) 2008-09-17 2017-09-22 Chiasma Inc. Farmaceutski pripravci i odgovarajući postupci za isporuku
DE102009018133A1 (de) * 2009-04-15 2010-11-11 Agon Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
GB201306720D0 (en) * 2013-04-12 2013-05-29 Special Products Ltd Formulation
AU2016215350B2 (en) 2015-02-03 2021-11-25 Amryt Endo, Inc. Method of treating diseases
WO2016174664A1 (en) 2015-04-29 2016-11-03 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102419769B1 (ko) 2016-08-11 2022-07-13 아다미스 파마슈티칼스 코포레이션 약물 조성물
EP3299017A1 (en) * 2016-09-23 2018-03-28 The Boots Company PLC Formulation
CN107397719A (zh) * 2017-08-16 2017-11-28 洛阳市兽药厂 一种畜禽用奥美拉唑可溶性粉剂及其制备工艺
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
GB201804621D0 (en) * 2018-03-22 2018-05-09 Bcm Specials Ltd Formulation
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
GB202116644D0 (en) 2021-11-18 2022-01-05 Innovate Pharmaceuticals Ltd Liquid composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
EP0425505B1 (en) * 1988-06-30 1993-03-17 The Upjohn Company Transdermal antisecretory agents for gastrointestinal disease
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs

Also Published As

Publication number Publication date
EE03473B1 (et) 2001-08-15
TR199701117T1 (xx) 1998-02-21
PL322619A1 (en) 1998-02-02
AU703755B2 (en) 1999-04-01
EP0819004A1 (en) 1998-01-21
HU227864B1 (en) 2012-05-29
KR100419105B1 (ko) 2004-05-31
EA199700294A1 (ru) 1998-02-26
CY2613B2 (en) 2011-04-06
HUP9801626A3 (en) 2000-06-28
ZA962657B (en) 1996-10-09
SK282872B6 (sk) 2003-01-09
HUP9801626A2 (hu) 1999-02-01
SK135097A3 (en) 1998-06-03
NO974589L (no) 1997-12-03
HK1004658A1 (en) 1998-12-04
IS4576A (is) 1997-10-02
SI0819004T1 (sl) 2009-12-31
NZ305708A (en) 1999-11-29
CZ313597A3 (cs) 1998-04-15
ATE438380T1 (de) 2009-08-15
EE9700244A (et) 1998-04-15
IS2706B (is) 2011-01-15
PT819004E (pt) 2009-10-12
AU5379796A (en) 1996-10-23
CN1185107A (zh) 1998-06-17
NO312994B1 (no) 2002-07-29
CA2217515C (en) 2005-03-15
DK0819004T3 (da) 2009-11-30
KR19980703576A (ko) 1998-11-05
CA2217515A1 (en) 1996-10-10
DE69637985D1 (de) 2009-09-17
JP4603631B2 (ja) 2010-12-22
CZ287297B6 (en) 2000-10-11
WO1996031213A1 (en) 1996-10-10
JPH11503160A (ja) 1999-03-23
PL183144B1 (pl) 2002-05-31
US5708017A (en) 1998-01-13
EA000087B1 (ru) 1998-06-25
CN1080119C (zh) 2002-03-06
BR9604803A (pt) 1998-06-09
EP0819004A4 (en) 2006-01-18
ES2329098T3 (es) 2009-11-20
MX9707694A (es) 1997-12-31
EP0819004B1 (en) 2009-08-05
NO974589D0 (no) 1997-10-03

Similar Documents

Publication Publication Date Title
UA42061C2 (uk) Фармацевтична композиція для перорального введення, що містить інгібітори протонного насоса
IS1694B (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
ATE252899T1 (de) Schilddrüsenhormone enthaltende mittel
ATE345782T1 (de) Dosierungsformen enthaltend geschmacksmaskierten wirkstoffen
ATE225647T1 (de) Dosierungsform zur verabreichung von flüssige arzneimittel formulierung
RU95109905A (ru) Композиции в жидком, полутвердом, твердом, гелеобразном или пастообразном виде и способ лечения заболеваний полости рта
AR022930A2 (es) MICROCAPSULAS, DE TIPO RESERVORIO, QUE CONTIENEN POR LO MENOS UN PRINCIPIO ACTIVO MEDICAMENTOSO Y/O NUTRITIVO (PA) CON EXCLUSION DEL ACIDO ACETILSALICILICO (ASA), DESTINADAS A LA ADMINISTRACION POR VIA ORAL, SU UTILIZACIoN Y FORMA FARMACEUTICA QUE COMPRENDE A DICHAS MICROCAPSULAS.
BG100933A (en) Polymer coated tablets comprising amoxycilin and clavulanate
BG105754A (en) Pharmaceutical composition containing proton pump inhibitors
EP1365749A4 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
TR199701294T1 (xx) Amoksisilin ve klavulanik asitten olu�an terkip.
DK0969843T3 (da) Antitussive formuleringer indeholdende theobromin
PH27446A (en) Compound with gastric acid inhibitory effect
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado
MY100780A (en) Azumolene dosage form.
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
MY102368A (en) Solid sustained-release composition
KR890001567A (ko) 디플루니살 및 트로메타민-함유 조성물
ECSP961835A (es) Nuevo procedimiento
JO1881B1 (en) Formula II for multi unit disc calibration